

**Erin W. Hofstatter MD**  
Co-Director, Smilow Cancer Genetics and Prevention Program  
Yale School of Medicine/Yale New Haven Hospital



Dr. Erin Hofstatter is an Associate Professor of Medicine in the section of Medical Oncology at Yale School of Medicine, where she serves as a breast cancer medical oncologist with a clinical specialty and research interest in breast cancer risk and prevention. Over her career, Dr. Hofstatter hopes to discover new genetic, epigenetic and epidemiologic profiles that may better identify those women at increased risk of breast cancer, with a goal of decreasing breast cancer incidence by improving utilization of breast cancer prevention strategies. Her research is unique among most academic medical oncologists, given its focus on cancer prevention.

Dr. Hofstatter received her BA in Biology from Amherst College in 1997. Following completion of medical school at University of Connecticut, she went on to internal medicine residency at Mount Auburn Hospital/Harvard Medical School and completed her fellowship in Hematology/Oncology at Beth Israel Deaconess Medical Center in 2010. Dr. Hofstatter then joined the faculty at Smilow Cancer Hospital/Yale School of Medicine, where she specializes in breast oncology and clinical breast cancer genetics and prevention.

Dr. Hofstatter's current research activities include her work on her investigator-initiated clinical/translational research project examining the role of epigenetics and premature breast tissue aging in breast cancer risk. This project has been generously supported by the Terri Brodeur Breast Cancer Research Foundation, and has led to her recent recognition for her research contributions through the 2016 National Cancer Institute's Cancer Clinical Investigator Team Leadership Award. Dr. Hofstatter's other research activities include the development of a robust clinical genetics database and specimen biorepository for further investigations into novel hereditary cancer genes. Dr. Hofstatter is also planning

an investigator-initiated clinical trial examining the role of PARP inhibition in the treatment of BRCA-related breast cancer, and serves as Principal Investigator on several national breast cancer clinical trials.

In addition to her clinical and research efforts, Dr. Hofstatter was appointed in July 2014 as Co-Director of the Smilow Cancer Genetics and Prevention Program, a new clinical and research initiative to provide multidisciplinary care to patients at increased risk of cancer. Dr. Hofstatter's goal is to develop a comprehensive, integrated program unifying cancer genetic counseling services with clinical cancer high-risk/prevention initiatives. Dr. Hofstatter also serves as a teacher and lecturer, having given over 50 academic lectures on breast cancer genetics and prevention on the local, regional and national levels, and providing practice-based education and clinical research mentorship to oncology fellows, residents and medical students.

A Connecticut native since childhood, Dr Hofstatter moved to the New Haven area in 2010 after completing her medical training in Boston. She is married with 2 children, Greg (age 11) and Sarah (age 6). She enjoys spending her free time at home with family and friends.